Clinical Trials

60 enrolled

Nasopharyngeal Carcinoma

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

460 enrolled

Nasopharyngeal Carcinoma

NCT04522050 2023-07-12

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Phase 1 Unknown

65 enrolled

Nasopharyngeal Carcinoma

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT04898374 2022-08-17

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

120 enrolled

Nasopharyngeal Carcinoma

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT03707509 2022-07-01

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

263 enrolled

Nasopharyngeal Carcinoma

NCT03366415 2022-03-04

Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC

420 enrolled

Nasopharyngeal Carcinoma

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1 Unknown

91 enrolled

Nasopharyngeal Carcinoma

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

118 enrolled

Nasopharyngeal Carcinoma

NCT02627807 2020-06-16

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Phase NA Unknown

386 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04414566 2020-06-04

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

562 enrolled

Nasopharyngeal Carcinoma

NCT03403829 2019-07-08

Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage

360 enrolled

Nasopharyngeal Carcinoma

NCT03601975 2019-02-04

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

336 enrolled

Nasopharyngeal Carcinoma

NCT03639467 2018-09-18

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

40 enrolled

Nasopharyngeal Carcinoma

NCT01872962 2018-04-24

Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

480 enrolled

Nasopharyngeal Carcinoma

NCT02761291 2016-05-16

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1 Unknown

18 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence, Epstein-Barr Virus Infections, Multiple Acyl Coenzyme A Dehydrogenase Deficiency

NCT01915134 2015-01-01

Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma

362 enrolled

Nasopharyngeal Carcinoma

NCT01417390 2014-03-07

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

80 enrolled

Nasopharyngeal Carcinoma

NCT01854203 2013-07-30

NPC

Phase 2/3 Unknown

300 enrolled

Nasopharyngeal Carcinoma

NCT01655628 2012-08-02

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

40 enrolled